Peihong Hsu

Dr. Peihong Hsu

Auto-generated profile, based on publicly available information

Dr. Peihong Hsu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2021 in Haemophilia
Verified
Journal Article
Closed access
PDF file
JAJameel Abdulrehman
Jameel Abdulrehman
YZYonah C. Ziemba
Yonah C. Ziemba
PHPeihong Hsu
Peihong Hsu
ECElizabeth M. Van Cott
Elizabeth M. Van Cott
EPElizabeth A. Plumhoff
Elizabeth A. Plumhoff
RSRita Selby
Rita Selby

1 January 2006
Verified
Journal Article
Closed access
LLLin Li
Lin Li
PHPeihong Hsu
Peihong Hsu
KPKeyur Patel
Keyur Patel
YSYasi Saffari
Yasi Saffari
IAIda Ashley
Ida Ashley
JBJudith Brody
Judith Brody

30 July 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NMNeda Mirzamani
Neda Mirzamani
XZXinmin Zhang
Xinmin Zhang
JBJudith Brody
Judith Brody
SSSilvia G. Spitzer
Silvia G. Spitzer
FSFiliz Sen
Filiz Sen
PHPeihong Hsu
Peihong Hsu
Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (CHL) are of B-cell origin. In a small number of CHL cases, the tumor cells can express T-cell antigens. CD8 expression in this setting is extremely rare. We identified 5 cases of CHL with aberrant CD8 expression from our database. The patients included 3 men and 2 women with a median age of 33 years (range = 20-59 years). All the patients initially presented with lymphadenopathy and variable number of RS cells. Two cases were classified as mixed cellularity type that showed prominent vascular proliferation mimicking peripheral T-cell lymphoma. Two cases represented nodular sclerosis type. The tumor cells in all cases were positive for CD8 and negative for CD2, CD3, CD4, and CD7 and carried germline T-cell receptor genes. Molecular studies revealed T-cell receptor genes to be in germline configuration in 4 cases with available information. Given the morphologic overlap with peripheral T-cell lymphoma and the rarity of this type of CHL, identifying more cases will help our better understanding of this entity.

Verified
Journal Article
Open access
PDF file
NSNeha Seth
Neha Seth
JBJudith Brody
Judith Brody
PHPeihong Hsu
Peihong Hsu
JKJonathan Kolitz
Jonathan Kolitz
PDPratik Q Deb
Pratik Q Deb
XZXinmin Zhang
Xinmin Zhang
Background: Genetic alterations in CSF3R, typically associated with chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML), rarely occur in other myeloid neoplasms. Methods: This study characterized the clinical, morphologic, cytogenetic, and molecular features of 13 patients with non-CNL non-aCML myeloid neoplasms with CSF3R alterations. Patients (median age, 77 years) were categorized into groups with a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (n = 5), acute leukemia (n = 4), and other myeloid neoplasms (n = 4) based on the WHO 2022 and ICC criteria. Results: The CSF3R p.Thr618Ile mutation was most frequent (11/13), with additional pathogenic variants including p.Gln743Ter and frameshift mutations affecting the cytoplasmic tail. Variant allele frequencies (VAFs) ranged from 2% to 49%, with the highest median VAF in the MDS/MPN group. Co-mutations varied by subtype; MDS/MPN, NOS, and CMML cases frequently harbored mutations in epigenetic regulators (ASXL1, TET2) and splicing factors (SF3B1, SRSF2, ZRSR2), while acute leukemia cases showed alterations in JAK3, STAT3, and NRAS. Survival analysis revealed distinct patterns across the three diagnostic groups, with MDS/MPN having the poorest prognosis. Conclusion: This study expands the recognized spectrum of CSF3R-related myeloid neoplasms and highlights the clinical and molecular heterogeneity associated with these mutations, emphasizing the need for comprehensive molecular profiling and the potential for targeted therapies.

20 January 2022 in Clinical Pathology
Verified
Journal Article
Open access
DWDongling Wu
Dongling Wu
XZXinmin Zhang
Xinmin Zhang
YZYonah Ziemba
Yonah Ziemba
NHNina Haghi
Nina Haghi
JBJudith Brody
Judith Brody
PHPeihong Hsu
Peihong Hsu
Background: Coronavirus disease 2019 (COVID-19) patients with severe disease had a high mortality rate. It’s imperative to identify risk factors associated with disease progression and prognosis. Immune responses played an important role in the host’s defense against the virus. We studied the dynamics of peripheral blood lymphocytes (PBLs) in relation to the clinical outcome in COVID-19 patients in intensive care unit (ICU). Design: This cohort included 342 COVID-19 patients who were admitted to ICU between February 1 and May 30, 2020, with 178 having follow-up PBL analysis. The patients were divided into a group that survived and an expired group. PBL analysis was performed by flow cytometry. Results: At time of initial flow analysis, there were no statistically significant differences in lymphocyte, T-cell and subsets, B-cell or natural killer (NK) cell counts between the 2 groups. However, during the ICU course, the surviving group demonstrated a full recovery of CD3+ T-cells, CD4+ T-cells, and CD8+ T-cells, with no significant change in B-cells, and a slight upward trend in NK-cells. In contrast, the expired group showed no recovery in T-cells (and subsets) and no significant changes in B-cells and NK-cells. We identified the earliest time points and cut-off values for T-cell subsets that predict clinical outcomes. Conclusion: The results of this study suggest that evaluation of PBL in COVID-19 patients could be valuable in the study of the immune responses to the disease and the prognostication of outcome.

7 March 2026 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
NSNeha Seth
Neha Seth
ZHZarrin Hossein‐Zadeh
Zarrin Hossein‐Zadeh
SQSyed Hassaan Ahmed Qasid
Syed Hassaan Ahmed Qasid
AGAngela Gi
Angela Gi
XZXinmin Zhang
Xinmin Zhang
PHPeihong Hsu
Peihong Hsu